3 oktober, 2019
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses study findings which showed that cabazitaxel improved radiographic progression-free survival as well as overall survival in patients with metastatic castration-resistant prostate cancer (Abstract LBA13).
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
in NEJM (The New England Journal of Medicine)
© 2021, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer | log in